Researched and relatable, science-driven and social, you re an extroverted expert.
DBV is a global biopharmaceutical company dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments.
DBV Technologies is developing Viaskin , a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT that delivers biologically active compounds to the immune system through intact skin. DBV s food allergy programs include late stage clinical trials of Viaskin Peanut and Viaskin Milk, as well as preclinical development of Viaskin Egg.
DBV is focused on becoming the leader in discovering, developing and commercializing food allergy products. Its pipeline development strategy is based on leveraging Viaskin s scientific profile while taking into consideration a combination of target market characteristics, which include allergen prevalence, persistence and severity. DBV s lead product candidate, Viaskin Peanut, is currently being evaluated as a treatment for peanut allergic children four to 11 years of age in a global Phase III program. Viaskin Peanut has obtained fast track designation and breakthrough therapy designation in children from the U.S. FDA. The EMA has also adopted a positive opinion with respect to a Pediatric Investigation Plan for Viaskin Peanut.
In addition to its development programs in food allergies (Peanut phase III, Milk phase II and Egg ending preclinic), DBV is also exploring potential applications of the Viaskin platform in other areas, including vaccines and immune diseases. DBV also launched a Phase IIa clinical trial assessing the safety and efficacy of Viaskin Milk for the treatment of milk-induced EoE. Beyond its core activities, DBV is also evaluating the use of its technology platform in the development of diagnostic tools for food allergies.
DBV has solidified its presence in the U.S. with the onboarding of top-level Commercial talent and the establishment of a brand new, state of the art facility in Summit, New Jersey. The company s Global Chief Commercial Officer is based in the US. DBV also has a representative office in New York City.
DBV Technologies (NASDAQ: DBVT, Euronext: DBV) is a publicly-traded biotechnology company based in France and the US.